| HOME >> MEDICINE >> TECHNOLOGY |
4.2 Development of Biologics and Vaccines Will Drive the Lyophilisation Market, 2011-2021
4.3 The Leading Sectors of Biological Drugs Market in 2010
4.3.1 Monoclonal Antibodies Currently Lead the Biotech Market
4.3.1.1 Long-Term Prospects for Monoclonal Antibodies and Implications for the Lyophilisation Market
4.3.2 The Human Insulins Class Will Exhibit Strong Growth
4.3.3 Erythropoietin Products - How Will Reported Safety Affect Sales?
4.3.3.1 Erythropoietin Products Forecast, 2011-2021
4.3.4 The Interferons Class will Show an Increase in Revenues from 2010-2015
4.3.4.1 Long-Term Forecast for the Interferons Class
4.3.5 Granular-Colony Stimulating Factors (G-CSF), 2011-2021
4.3.6 Recombinant Coagulation Factors Will Show Steady Growth
4.3.7 Other Therapeutic Proteins
4.3.8 Biosimilars Market, 2010
4.3.8.1 Forecast for the Biosimilars Market, 2011-2021
4.3.9 Vaccines Market, 2010-2021
5. Systems, Consumables and Service Providers in the Lyophilisation Industry and Market
5.1 Products and Services in the Lyophilisation Market
5.1.1 Equipment Providers
5.1.2 Consumables Providers
5.1.3 Contract Manufacturing Organisations (CMOs) Providing Lyophilisation Services
5.2 Profiles of Some Leading Companies
5.2.1 GEA Lyophil
5.2.1.1 Overview
5.2.1.2 Capabilities of GEA Lyophil
5.2.1.3 GEA Lyophil's Research and Development Freeze Dryers
5.2.1.4 GEA Lyophil's Pilot Freeze Dryers
5.2.1.5 GEA's Lyovac Production Lyophilisers
5.2.1.6 Lyophilisation Production Systems
5.2.1.7 GEA's Retrofits of Lyophilisers
5.2.1.8 GEA's VAPOVAC: Technology for Freeze Dryer Sterilisation
5.2.1.9 ALUS: GEA Lyophil's Automatic Loading and Unloading Systems for Lyophilisers
5.2.1.10 GEA's Thermodynamic Lyophilisation Control
5.2.1.11 GEA Ly
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |